• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc.

    5/27/25 7:01:17 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email
    DEFA14A 1 defa14a-proxysupplement2025.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 14A
    (Rule 14a-101)
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.    ) 
    Filed by the Registrant  x                Filed by a Party other than the Registrant  o 
    Check the appropriate box:
     
    o 
     Preliminary Proxy Statement
    o 
     Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    o 
     Definitive Proxy Statement
    x  
     Definitive Additional Materials
    o 
     Soliciting Material Pursuant to §240.14a-12
    Vanda Pharmaceuticals Inc.
    (Name of Registrant as Specified in its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    x
    No fee required.
    o
    Fee paid previously with preliminary materials.
    o
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.




    Vanda Pharmaceuticals Inc.
    2200 Pennsylvania Avenue NW, Suite 300E
    Washington, D.C. 20037

    SUPPLEMENT TO PROXY STATEMENT FILED ON APRIL 25, 2025 FOR THE ANNUAL MEETING OF STOCKHOLDERS
    To Be Held on June 5, 2025
    This proxy statement supplement, dated May 27, 2025, supplements the definitive proxy statement (the “Proxy Statement”) filed by Vanda Pharmaceuticals Inc. (the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”) on April 25, 2025, and made available to the Company’s stockholders in connection with the solicitation of proxies by the Board of Directors of the Company (the “Board”) for the 2025 Annual Meeting of Stockholders to be held on June 5, 2025 and any adjournment or postponement thereof (the “Annual Meeting”).
    This supplement is being filed with the SEC and is being made available to stockholders on or about May 27, 2025. Only stockholders of record at the close of business on April 15, 2025, or their duly designated proxies, may vote at the Annual Meeting.
    Except as described in this supplement, the information provided in the Proxy Statement continues to apply. To the extent that information in this supplement differs from or updates information contained in the Proxy Statement, the information in this supplement is more current. The Proxy Statement contains important additional information. This supplement should be read in conjunction with the Proxy Statement.
    Explanatory Note
    The Company is filing this proxy supplement to provide additional information to stockholders regarding (1) the Board’s determination that it was in the best interests of the Company and its stockholders for director Phaedra Chrousos to remain on the Board and continue to serve, notwithstanding her failure to receive a majority of the votes cast at the Company’s 2024 Annual Meeting of Stockholders and (2) the Company’s discussions with stockholders regarding that determination. The Company decided to file this proxy supplement after being notified of the contents of a proxy advisory firm’s voting recommendation report, which necessitated the clarification of the public record in the interests of accuracy.
    In its Current Report on Form 8-K, filed with the SEC on May 24, 2024 (the “8-K”), the Company (1) disclosed that, pursuant to the majority voting and advance resignation provisions of the Company’s Corporate Governance Guidelines, Ms. Chrousos had tendered to the Board her conditional resignation as a director and (2) set forth the Board’s rationale for not accepting Ms. Chrousos’ offer to resign. In that 8-K, the Company stated “[i]n accordance with the Corporate Governance Guidelines, the Nominating/Corporate Governance Committee of the Board (the “Committee”) is required to expeditiously consider the conditional resignation and recommend to the Board whether to accept or reject Ms. Chrousos’ resignation, and the Board is required to promptly act on such resignation, taking into account the Committee’s recommendation.” The disclosure continued “[t]he Committee considered Ms. Chrousos’ conditional resignation and recommended that the Board reject her conditional resignation. Ms. Chrousos was not present for, and did not participate in, the deliberations regarding her conditional resignation. In making this determination, the Committee considered all factors believed relevant including, without limitation, the following:
    •the relatively small margin by which Ms. Chrousos failed to be re-elected;
    •the fact that a proxy advisory firm recommended a vote for Ms. Chrousos;
    •the fact that the Company’s largest stockholder voted for Ms. Chrousos;
    •the tenure and qualifications of Ms. Chrousos, including her consumer healthcare experience and entrepreneurship, extensive executive experience in a variety of industries and her leadership experience within the federal government;
    •Ms. Chrousos’ past and expected future contributions to the Board;
    •the overall composition of the Board; and
    •the anticipated difficulty of finding, in a timely manner, a replacement director with similar capabilities and experience.



    In addition, the Committee considered the events that led to Ms. Chrousos’ conditional resignation. As previously reported, Vanda believes that Ms. Chrousos receiving the support of less than a majority of the votes cast for her election was not related to her performance, but rather was related to a proxy advisory firm’s recommendations regarding a Rights Agreement entered into by the Company on April 17, 2024 (the “Rights Agreement”), which Rights Agreement expired on April 16, 2025. In response to the Rights Agreement, such advisory firm recommended stockholders vote, and certain institutional investors voted, against Ms. Chrousos’ re-election because she is the chair of the Nominating/Corporate Governance Committee.
    After considering all relevant factors, the Committee discussed its recommendation with the full Board. Following deliberation, the Board determined that the resignation of Ms. Chrousos would be detrimental to, and not in the best interests of, Vanda and its stockholders. In addition to the factors considered by the Committee, the Board also considered the fact that the Rights Agreement was adopted and approved unanimously by the entire Board and that Ms. Chrousos was not individually responsible for the adoption of the Rights Agreement. The Board (except for Ms. Chrousos, who did not participate in, and was not present for, the discussion or vote regarding her conditional resignation) unanimously voted on May 22, 2024 to decline Ms. Chrousos’ conditional resignation. Accordingly, Ms. Chrousos will continue to serve as a director of Vanda until Vanda’s 2027 annual meeting of stockholders or until Ms. Chrousos’ successor is duly elected and qualified, or until her prior death, resignation, retirement, disqualification or other removal.”
    Subsequent to this determination, the Board engaged with stockholders to gain insight into and address the concerns underlying Ms. Chrousos’ failure to receive majority support. During 2024 and early 2025, the Company engaged in discussions with a number of stockholders regarding overall corporate strategy as well as the context in which the Company had adopted the Rights Agreement. In these discussions, although certain stockholders expressed concerns regarding the adoption and/or continuation of the Rights Agreement, no stockholder expressed any concern about Ms. Chrousos’ qualifications to serve as a director of the Company or the Board’s determination not to accept her resignation. For example, in October 2024, representatives of the Company, including a member of the Nominating/Corporate Governance Committee of the Board, met with the Company’s largest stockholder (representing approximately 15% of the Company’s outstanding shares) and held a wide-ranging discussion. Topics discussed included the reasons behind the adoption of the Rights Agreement and Ms. Chrousos’ retention on the Board, as well as the structure and function of the Nominating/Corporate Governance Committee. The Board gave due consideration to this stockholder’s concerns and, as a result, one of the decisions that the Board subsequently made was to allow the Rights Agreement to lapse upon its expiration on April 16, 2025 rather than renew it.
    Based on the disclosure that was provided to the Company’s stockholders in the 8-K describing the process followed by the Board in reaching its decision not to accept Ms. Chrousos’ resignation, together with the fact that the Company did engage with its stockholders, including its largest stockholder, to gain insight into and address their concerns, the Board believes that its two director nominees are deserving of re-election and continues to recommend a vote “For” each of the nominees at the Annual Meeting.
    ADDITIONAL INFORMATION AND WHERE TO FIND IT
    On April 25, 2025, the Company filed the Proxy Statement and definitive form of proxy card with the SEC in connection with its solicitation of proxies from the Company’s stockholders. STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, THE ACCOMPANYING PROXY CARD AND OTHER DOCUMENTS FILED BY THE COMPANY WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders can obtain copies of the Proxy Statement, any amendments or supplements to the Proxy Statement and other documents filed by the Company with the SEC for no charge at the SEC’s website at www.sec.gov or by writing to the Company’s Corporate Secretary at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, D.C. 20037.
    Please note that any proxy card that you requested or that the Company delivered has not changed and may still be used to vote your shares in connection with the Annual Meeting. If you have already submitted your vote, you do not need to take any further action unless you would like to change your vote. Information on how to vote your shares and how to change your vote or revoke your proxy is contained in the Proxy Statement. The Company urges stockholders to vote their shares by using one of the methods described in the Proxy Statement.
    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 5, 2025:
    This supplement, the Proxy Statement, proxy card and Annual Report on Form 10-K for the fiscal year ended December 31, 2024 are available free of charge at www.proxyvote.com.

    Get the next $VNDA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FANAPT issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

      4/3/24 4:12:36 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

      Conference Call and Webcast to Follow WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens.  Vanda will host a conference call at 8:00 AM ET on Thursday, July 31, 2025, during which management will discuss the second quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9430387. The conf

      7/23/25 4:45:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

      WASHINGTON, June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). VCA-894A is being developed for a patient who was first diagnosed at the age of 5 with a rare subtype of CMT disease known as CMT2S.1 CMT2S is an inherited neuromuscular disorder that progressively leads to muscle w

      6/10/25 8:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

      WASHINGTON, May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025. The following will be presented: May 27, 2025 Presentation Title: "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets"Poster Presentation Session: IIPoster Number: T19Presenter: Sean R. Chadwick, PhD, Clinical Development A

      5/27/25 9:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Vanda Pharmaceuticals Inc.

      SCHEDULE 13G - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      7/1/25 4:31:03 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Vanda Pharmaceuticals Inc.

      144 - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      6/13/25 9:40:59 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Vanda Pharmaceuticals Inc.

      S-8 - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      6/5/25 4:46:16 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      6/16/25 9:10:04 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      6/9/25 5:36:16 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chrousos Phaedra was granted 59,225 shares, increasing direct ownership by 92% to 123,350 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      6/9/25 5:35:49 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      5/21/25 9:23:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      5/19/25 5:13:38 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/6/25 5:53:21 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

      H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

      10/31/24 6:31:19 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00

      7/11/24 7:49:37 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals downgraded by Jefferies with a new price target

      Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously

      2/25/22 4:56:52 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

      WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin

      3/17/23 7:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      2/13/24 5:16:07 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      2/13/24 10:53:14 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      2/9/24 9:59:19 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Financials

    Live finance-specific insights

    See more
    • Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

      Conference Call and Webcast to Follow WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens.  Vanda will host a conference call at 8:00 AM ET on Thursday, July 31, 2025, during which management will discuss the second quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9430387. The conf

      7/23/25 4:45:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

      Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g

      5/7/25 4:01:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

      Conference Call and Webcast to Follow WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754. The conference

      5/2/25 8:46:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care